Epidemiological Study in Subjects With Vulvovaginal Candidiases
Estudio epidemiológico de la evolución clínica y microbiológica en Pacientes Tratadas Por un Episodio Agudo de Candidiasis Vulvovaginal
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Madrid, Spain, 28009
- Instituto Palacios
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Sexually active women between 18 and 50 years of age at time of screening
- With diagnosis and symptomatology of VVC
Exclusion Criteria:
- Pregnant women
- Diabetes Mellitus
- Women witihin three months after a delivery or misbirth
- Women with vaginal or genital infection symptomatology other than candidiases that needs antibiotic treatment
- Vaginal probiotics use within last three months
- Undiagnosed abnormal genital hemorrhage
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Women with candidiases infection
Women that are prescribed treatment with clotrimazole: 500 mg.
and probiotics (routine clinical practice)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Estimate cure rate in women with severe vuvovaginal candidiases infection
Time Frame: At 3 months
|
Women must require antimicotic treatment plus vaginal probiotic following the habitual therapeutic standards
|
At 3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Estimate recurrences
Time Frame: At 6 months
|
It will be consider recurrences an asymptomatic period for 7-10 days and a negative culture
|
At 6 months
|
|
Estimate recurrences
Time Frame: At 12 months
|
It will be consider recurrences an asymptomatic period for 7-10 days and a negative culture
|
At 12 months
|
|
Evaluate the link between symptomatology and negative culture
Time Frame: At 3 months
|
At 3 months
|
|
|
Evaluate the effectiveness of probiotic treatment by physician
Time Frame: At 3 months
|
A gynecological exploration will be performed
|
At 3 months
|
|
Evaluate the effectiveness of probiotic treatment by patient. A satisfaction questionnaire will be performed
Time Frame: At 3 months
|
The subject will be asked how long the symptoms lasted and the gravity of them
|
At 3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IP-01-2016
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.